NEW DELHI: Alembic Pharmaceuticals today reported nearly 4-fold jump in its consolidated net profit to Rs 269.49 crore for the quarter ended December 31, mainly on account of robust sales in the overseas market.
The company had posted net profit after tax and share of profit/loss of associates of Rs 70.66 crore for the October- December period of the previous fiscal, Alembic said in a filing to the BSE.
Consolidated total income from operations of the company rose to Rs 921.73 crore for the October-December quarter of the current fiscal, as against Rs 511.78 crore for the year ago period.
Alembic’s Joint MD Shaunak Amin said: “We have seen exceptional growth in all our businesses. The US business continues to outperform on the back of Aripiprazole generic launch.”
The company stock closed at Rs 625.65, up 6.48 per cent, on the BSE.